Seek President and CEO. Quantitative Radiology Solutions (QRS) (doing business as Quantaras) provides body-wide analysis of medical images to personalize cancer treatment decisions. Our unique Automatic Anatomy Recognition (AAR) software supports recognition and analysis of anatomical objects and diseased tissue in multiple body regions using MRI, CT, and PET/CT images. Our first application aims to reduce side effects for cancer patients undergoing radiation therapy, and the application has been validated at 4 academic medical centers. QRS received FDA clearance for this application in April 2021. The management team at QRS combines business, product development and industry experience to systematically de-risk innovations and bring regulatory cleared products to the market.
Current delivery platforms for RNA and gene editing technologies induce off-target effects and fail to specifically target tissue types. Led by Columbia’s Dr. Fatemeh Momen-Heravi and Dr. Akiva Mintz, the Enviar team has recently developed a novel customizable delivery platform—called SafeExo—based on engineered exosomes. Exosomes naturally carry biomacromolecules including different RNAs (mRNAs, regulatory miRNAs, etc.), DNAs, lipids, and proteins and can deliver their cargoes to the recipient cells, elicit functions, and mediate cellular communications. SafeExo is the first engineered exosome platform capable of eliminating endogenous nucleic acids, which greatly reduces off-target effects. SafeExo is further optimized to enhance RNA stability, CRISPR efficacy, target uptake and specific cell/tissue delivery of large payloads, such as targeted CRISPR/CAS gene editing machinery and RNAi therapeutics. This platform has the potential to treat new diseases and improve current therapies.
Note: No company is formed yet. Seeking entrepreneur to lead. Opioids remain an indispensable treatment for severe pain despite increased risk for obese patients with tolerance. Of particular concern is opioid-induced respiratory depression (OIRD), especially during sleep, due to comorbid obstructive sleep apnea common in obese patients. Naloxone is the only drug available that can reverse the adverse effects of opioids and prevent death. However, naloxone has limited use because it reverses analgesia and induces withdrawal. A preventive treatment for sleep-related OIRD that does not affect analgesia or induce withdrawal is critical in patients with obesity. GW and JHU researchers found that intranasal leptin can reverse morphine-induced apneas, hypoventilation, and upper-airway obstruction while enhancing analgesic effects in mice with obesity.
Our company, Impact Proteomics, makes protein sample preparation kits to provide researchers in the pharmaceutical and biotechnology industries with high quality protein samples faster than ever, improving research reproducibility and saving time and money. High quality protein preparations are essential for drug and biomarker discovery, monitoring therapeutic efficacy, biologic drug quality control, and for understanding fundamental cellular processes. For decades, industry and academia have been hindered by incomplete and irreproducible protein sample preparation. These samples are often contaminated with other cellular components and incompatible reagents, such as DNA, salts, and the reagents used to break open cells. Fast, high quality sample preparation can mean the difference between finding a lifesaving drug target or wasting millions of dollars and decades of time on a failed drug discovery project. Impact Proteomics is here to ensure every project reaches its potential.
Overview DNA methylation-based biomarkers have great potential to transform the diagnosis, monitoring, and treatment of cancer and other diseases. DNA methylation is an epigenetic mechanism used by cells to control gene expression. During DNA methylation, methyl groups are added to the DNA molecule, changing the DNA activity but not the sequence. Errors in methylation have been linked to a variety of diseases. Currently, clinicians use DNA methylation tests to screen for certain genetic changes that can affect processes such as methionine metabolism and hormone balance. Market Opportunity Few DNA methylation-based biomarkers have been successfully translated into clinical practice. There is limited technology to assess epigenetic information cost effectively at a large scale. Leukocytes, or white blood cells, mount the immune response to pathogens and foreign antigens. Until now, the distribution of leukocytes has been determined by examination under a microscope or with a flow cytometer.
Pain is the second largest burden on the US health care system, and with the advent of the opioid epidemic it has become apparent that patients with chronic pain do not have sufficient treatment options. A proven non-pharmaceutical method of pain treatment is through nerve and spinal cord stimulators, which are devices that are implanted in the body and use electrical signals to control and modulate the perception of pain. In addition, patients report that their pain is controlled long after electrical stimulation has stopped, and the nerve stimulator market has grown to over $3Billion per year. However, these stimulators often require surgery to implant, can cost more than $30,000 and have excessively high failure rates which are estimated to be over 30%, requiring revision operations and rapidly increasing costs to over $100,000 for a single device.
73.6% (250m people) of the American Population is overweight or obese. Weight disorders place a significant burden on the healthcare system due to increased risk of deleterious disorders such as diabetes, kidney failure, liver failure, cardiovascular disease, and COVID-19. A key issue in reducing weight gain in the population is that weight loss therapies are not covered by insurance, unless patients are severely obese or possess multiple co-morbidities, requiring patients to pay nearly $1,500/month. Considering that persons in lower socio-economic standing are more likely to be overweight or obese, it is unsurprising that the prevalence of obesity continues to rise. These expensive weight loss therapies aim to alter an individual’s metabolism, which is very difficult to accomplish and often yields significant side effects with long-term use.
Stroke is an incredibly pervasive problem that directly affects one quarter of the world’s population. Unfortunately, many of these people are told they will never regain functional use of their arm or hand. With Reach, they will. One of our patients was able to cut food with a fork and knife and feed herself for the first time in 9 years since having her stroke. In contrast to existing assistive tools such as functional electrical stimulation, Reach’s device allows the user full control over complex and naturalistic movements. Advantages of the technology: • Assists movements in all upper limb joints • Restores naturalistic and voluntary movements • Immediate improvements • Assists users in performing tasks of daily living • Eligible for chronic stroke patients even years after their stroke • Uses standard implant device and surgical procedure • Does not require donning and doffing bulky equipment
Ventilator Associated Pneumonia (VAP) is viewed as an inevitable consequence of long-term ventilator support rather than a preventable infection. In fact, VAP develops in 1 out of 3 intubated patients in intermediate care units. Along with the high prevalence, VAP has an average mortality rate of almost 50%. As a result, hospitals utilize procedural steps to prevent VAP in patients (such as head elevation and maintaining oral hygiene), but these actions fail to adequately prevent the root cause of VAP which is that current endotracheal (ET) tubes, or breathing tubes, do not create a long-term and effective seal in the trachea to prevent bacteria from entering the lungs. These tubes fail to create a proper seal because they employ an inflatable cuff that (1) deflates over time, (2) does not maintain consistent contact with the airway surface, and (3) is susceptible to shifting position with every patient movement. These design flaws allow harmful bacteria to pass the cuff and enter the lungs of patients.
ChromaTiR (color through total internal reflection) is developing a technology to create color-shifting effects in a broad range of materials that is more cost-effective and safer. They are working to advance their patent-pending technology, which allows the use of a low-cost, simplified and more customizable method to generate vibrant, iridescent coatings in which no nanoparticles and no metal films are used. ChromaTiR offers customizable color shifting special effect coatings and pigments with tunable color profiles and large angular separation between colors.
South Rampart Pharma aims to advance the safe treatment of pain by developing new small-molecule solutions that have the potential to overcome many risks associated with current pain medicines. South Rampart Pharma’s lead compounds have been effective in reducing both pain and fever in preclinical studies without the liver and kidney toxicity associated with current non-opioid analgesics. As a new small molecule treatment option that is not a biologic therapy, South Rampart Pharma’s compounds have great potential as a value product that will be low cost and accessible to many patients.
Millions of people all over the world face challenges with alcohol. One of the more traditional solutions people first consider is Alcoholics Anonymous. Through market research, we have learned that more and more non-traditional solutions are being sought out to supplement the recovery journey and we, at Milo Sensors, believe we can provide an option for the supervised or self-monitoring of alcohol consumption. Unlike other existing alcohol monitoring tools such as ankle bracelets, ION™ is designed for the wearer first, with discretion, comfort, and usability at the forefront. Common industries that benefit from similar monitoring devices, such as the criminal justice system or family law, seem to follow only after the recovery support network has failed and act as a punitive measure. In contrast, we aim to help anyone who seeks to improve their general wellness by focusing on their relationship with alcohol and then help rebuild trust with surrounding family members and supporters.
smartHER is a mixed reality (MR/AR)-based medical device company focused on developing innovative solutions for gynecologic procedures, with an initial focus on rehauling how MRI scans are utilized for uterine fibroid removal. The company is spinning out of Weill Cornell Medicine (WCM) where it has gained significant traction by developing a MVP. It has received multiple awards for its novel product design, established strategic partners in several relevant domains (e.g., women med device, cloud computing, and MR software), and is in the process of validating the technology through a clinical study. smartHER is looking to hire its inaugural Chief Executive Officer (CEO).
Due to the rapidly growing use of opioids and its analogs (and the increase of fatal drug overdoses), Narcan is rapidly becoming the new Kleenex. Vaccines offer a promising treatment alternative to counteract opioid use disorders (OUD) and fatal overdoses. Vaccines generate opioid-specific antibodies that bind the target opioid, reducing the drug's impact on the brain and preventing the drug-induced effects. Futura is developing vaccines, antibody-based strategies, and small molecules to counteract opioid use disorders and overdose. These approaches can improve the lives of people living with substance use disorders or who are at risk of fatal overdoses. The team is testing the first in-human vaccine against the euphoric and toxic effects of oxycodone and have initiated Phase I Clinical Trials. Futura and UMN is seeking a leader co-found the venture with Dr. Pravetoni.
The heart is a muscle, and like all types of muscles, it can be injured. In humans, heart muscle is not able to regenerate after injury. This can lead to heart disease which develops over time, eventually leading to an untimely death. Prolifagen is combining discoveries in gene therapy, materials science, and drug delivery to bring human tissue regeneration therapies to reality. The lead drug candidate is a proprietary microRNA embedded in a hydrogel construct to enable a single-shot therapy for heart tissue regeneration, bypassing the need for exogenous stem cells. Prolifagen is seeking seed funding for IND-enabling porcine studies and a new CEO to lead the team into their next chapter.
The cellular industry has begun a transition toward open, programmable, and cloud-native architectures to reduce cost and address major management challenges. This transition (like the telecom migration to SDN) creates a significant new business opportunity for a flexible automated management system. zTouch Networks leverages years of research and development to provide the industry’s first data-driven, intelligent and autonomous network operating system to power this industry upgrade. The zTouch has extensive relationships with key industry partners and manages the world’s largest RF emulator, Colosseum (a $30M+ resource) and the testbeds in the NSF Platforms for Advanced Wireless Research (a $100M program). zTouch has an aggressive plan to pilot its platform in the next 18 months and is looking for partners and investors in this effort. It is looking to raise $5M to accelerate its pilot and add world-class leaders to run and grow the business.
Mitral regurgitation (MR) is the most common heart valve disorder in the US, with over 4 million individuals affected globally and an incidence of over 250,000 annually. Results of severe MR frequently lead to shortness of breath and fatigue and to potential heart failure and death without treatment. Open heart surgical Mitral valve repair (OHMVR), is the gold-standard option to restore the valve function and patient prognosis. Today minimally-invasive options (transcatheter therapy, TMVR) allow surgeons and interventional cardiologists to perform valvular repairs without opening a patient's chest and represent a safe alternative in a subset of frail patients. The MitralPrint device will be the first endovascular, piezoresistive pressure sensor designed to quantify myocardial contraction fraction (MCF) in real-time during both OHMVR and TMVR allowing the surgeon to record an objective parameter on the MR. This eliminates the need for subjective trans-thoracic ultrasound assessment.
Lubrication is critical in biology for tasks such as joint flexing and eye movement, but aging and disease can reduce natural lubrication. Current lubrication solutions either exhibit a short half-life (such as cortisone and hyaluronic acid) or poor long-term bio-compatibility (such as exogenous lubricants like glycerin-mineral oil), leaving a market opportunity to develop a durable, bio-compatible lubricant. synLubricin is a stable, and scalable, long-term bio-lubricant for joints, eyes, and medical devices. synLubricin has been developed in FDA-approved human cell culture systems and is able both to resist cellular adhesion and lubricate biological surfaces, such as cartilage. synLubricin is searching for a co-founder to help develop this venture opportunity.
Periodontitis is a chronic destructive inflammatory disease affecting up to 50% of Americans for which there are limited treatment options. The US market alone will be $900M for dental implants by 2024. Current treatment options for periodontitis include guided tissue regeneration, with non-absorbable, difficult to manipulate products. DontoFilm has developed a smart periodontal membrane with chemotactic coating which facilitates bone regrowth while staying flexible and resorbable.
Cell replacement therapies hold tremendous promise for type 1 diabetes, hemophilia, lysosomal storage diseases and other cellular disorders. EncapBio Systems has developed technologies for safe and functional delivery of cell therapies ready for pre-clinical development. Most of our recent work, ranging from material synthesis and device fabrication to cell engineering and process integration, has been centered around the goal of successfully delivering safely insulin producing cells with long-term function for T1D patients. EncapBio Systems builds upon 10 years of research of high quality proof-of-concept publications and patent applications. EncapBio Systems is seeking co-founders and investors to help build the next biomaterial platform for cell therapy.
Drug discovery remains an expensive and time-consuming process. Promising compounds proceed through clinical trials only to have many failures before FDA approval. Aracari’s vascularized microphysiological systems are leading the way in preclinical drug testing. Aracari’s vascularized 3D Vascularized Micro-Organ (VMO) and Micro-Tumor (VMT) models incorporate perfused human vasculature for the physiologic delivery of nutrients, drugs and immune cells to multiple tissue and tumor types. These powerful next-generation tools are accelerating development of immuno-oncological and other therapeutics for more optimal patient outcomes. Aracari is seeking a Chief Business Development Officer as they expand their C-level team.
Datacenters are a critical component of the modern internet, responsible for processing and storing tremendous amounts of data in the “cloud.” Datacenters also provide the computational power needed for handling “big data,” a growing segment of the U.S. economy. Xscape is making the next-generation photonic communication networks for high-performance computation. Such networks are crucial for data centers, machine learning, and artificial intelligence. Our technology is based on our world-leading photonic-chip technology combined with massive frequency-division multiplexing, which allows for ultrahigh bandwidth communications up to 25 times faster than products currently on the market. This scalable technology is smaller and less expensive than current products and requires less power. The scientific founders are seeking a dedicated CEO to build the company.
Mammalian cell tissue culture is critical to biomedical research and to the production of many blockbuster drugs. Animal-sourced sera provide the growth factors and cytokines that are essential for tissue culture. After an initial $1.5 million investment, TildenBio's photosynthetic platform is suited to producing biomedical proteins economically, simply, and at large scale. We have achieved expression levels of over 20% of total protein. TildenBio’s technology is simultaneously applicable to a number of markets, including the diagnostic market, edible vaccine market, industrial enzyme market, and possibly next-generation antibiotic markets. With an initial beachhead focused on producing low-cost growth factors and cytokines as replacements for animal-sourced tissue culture sera, TildenBio is searching for a CEO to lead the team into its next chapter.
Broad-spectrum antiviral therapies do not exist, tragically hindering our ability to respond to viral outbreaks and pandemics. We need new approaches to treat these diseases, as existing therapeutics are very narrow-spectrum and take many years to develop. Carver Biosciences is a startup company developing CRISPR-based therapies for RNA viruses that infect humans. Carver’s approach is a programmable, platform technology that could offer a generalizable solution for treating many viruses, as targeting is dictated by a guide RNA sequence. The underlying technology, CARVER, was developed by founder Cameron Myhrvold during his time as a postdoc at the Broad Institute of MIT and Harvard and was published in Molecular Cell in 2019. Carver recently closed a seed round and is looking to expand it's team.
WiLO Networks bridges the gap between passive RFIDs and high power Long Range (LoRa)/Sigfox to enable precision agriculture, military surveillance, fire mitigation, smart highways, and other IoT applications. Currently, WiLO Networks focus is to provide solutions for precision agriculture. WiLO Networks is building a novel physical layer communication technology based on low-power integrated circuits (ICs), which can be embedded in sensor nodes and gateways at very low cost. This physical layer technology combined with novel network architecture and protocols, as well as intelligent machine learning techniques promises a 10 year lifetime for sensor nodes powered on millimeter-scale batteries. These ultra-low power sensor networks are the key to precision agriculture, monitoring the health of buildings/bridges, and military surveillance. WiLO's solutions can reduce waste to promote sustainability and carbon neutrality.
Genome-wide association studies (GWAS) have identified thousands of noncoding variants associated with human traits and diseases. However, translating these variants into therapies continues to be a significant challenge. Alpaca Genomics has constructed a multi-tissue atlas of human 3′ UTR alternative polyadenylation (APA) quantitative trait loci (3′aQTLs), connecting thousands of noncoding GWAS variants with the APA of target genes, identified in 49 tissues isolated from 838 individuals (sourced from the Genotype-Tissue Expression Project). Alpaca Genomics is using 3’aQTLs to discover novel APA-linked susceptibility for many human diseases, such as diabetes, prostate cancer, coronary artery disease (CAD), Alzheimer’s Disease (AD), Parkinson's disease, and Amyotrophic lateral sclerosis (ALS).
Velox Biosystems plans to develop and launch a rapid diagnostic product for urinary tract infections (UTI), a problem that affects nearly 50 percent of the population at least once in their lifetime. This decision follows the startup’s completion of a recent clinical feasibility test that yielded impactful clinical data for the company to move forward with the next steps in development. Velox Biosystems has created an ultra sensitive rapid detection system that provides for no or minimal sample processing, high throughput scanning of large sample volumes, with single target sensitivity and unprecedented speeds. Utilizing a digital droplet molecular detection platform, we are developing a point of care diagnostic device to address critical unmet needs in the UTI, liquid biopsy, and sepsis spaces. Total available market of over $1 Billion.
AgingSense is a company focused on developing technological solutions to complex problems of aging to improve quality of life of older adults. The first technological solution being developed is Heart Failure Monitoring Socks. This wearable sock technology monitors persons with heart failure for exacerbations as well as response to treatment. The socks monitor for changes related to heart failure specifically, leg edema, using stretch sensors, and fatigue using actigraphy and gyroscopes. Data is sent by blue tooth to an app which is run through an algorithm in a secure cloud that triggers a message to the individual with HF, a trusted other and/or their provider of changes in their condition. The ultimate goal is to improve heart failure management to keep persons with heart failure home and out of the hospital with a better quality of life.
Tandem Repeat Technologies, Inc. (TR Tech) is the market leader in Sustainable Textiles Manufacturing. TR Tech has created the world’s first programable textile which is 100% sustainable, self-healing, and fully biodegradable. Established in 2018, TR Tech has developed revolutionary technology that combines materials science and biomanufacturing to produce performance composites with tunable properties. The technology is covered under five (5) issued US patents and additional five (5) pending with Squitex. The physical characteristics of Squitex will allow it to be adopted into many products and technologies. It is a platform performance material that is renewable, green, strong, flexible, self-healing, energy efficient and friendly to most of today’s manufacturing processes. The use will only be limited by the creativity of application and the ability to produce the quantity of material to meet market demand.
Sense4me is developing a digital platform that predicts relapse in patients with alcohol use disorder. Through wearable sensors, sense4me provides real-time measurements of a patient’s sympathetic nervous system and hypothalamus, data that can act as an alert to subdue cravings before they cause the patient to relapse. This just-in-time intervention powered by personalized health analytics has the potential to reduce relapse rates, which can be as high as 80-95% among patients in their first year of treatment for alcohol and nicotine addiction. Dysregulation of the stress system has been associated with a shorter time to future relapse in alcoholics. By monitoring stress responses, this technology empowers the 14.8M Americans with alcohol use disorder to actively participate in their treatment and take control of their cravings. A collaboration between Columbia’s Dr. Lili Deligianni and Dr. Nasir Naqvi, sense4me is seeking $500K in seed funding to complete a wearable prototype and accompanying software.
Lithium-ion (Li-ion) batteries are used in many products such as electronics, toys, wireless headphones, handheld power tools, small and large appliances, electric vehicles, and electrical energy storage systems. If not properly managed at the end of their useful life, they can cause harm to human health or the environment. Princeton NuEnergy is revolutionizing the material supply chain with its patented low-cost process for producing high quality cathode active materials from spent lithium ion batteries. With successful operation of our lab scale plant and strong relationships throughout the electric vehicle supply chain we are building out our team to execute our production scale manufacturing plants starting in 2021.
KneeMo addresses problems associated with musculoskeletal disorders including sports related injuries and chronic disease such as osteoarthritis (OA). The potential market is substantial since musculoskeletal disorders affect more than one out of every two persons in the United States over age 18 and three out of four over age 65. Osteoarthritis alone accounts for 242 million people in the world who live with activity limiting symptoms. Pharmaceuticals, often used to alleviate the musculoskeletal pain come with side effects that can include addiction. KneeMo takes a novel mechanical approach to engage multimodal sensory pathways that signal pain using cutaneous mechanical stimuli (e.g., vibration) where over stimulation in one mode of the system (e.g., vibration) can gate response in other modalities (e.g. pain). KneeMo was shown in a placebo controlled clinical trial to provide an effective and safe alternative to pharmacological interventions to reduce pain and enhance function.
Dermal fillers are implantable medical devices injected into the skin to help fill in facial wrinkles, restoring a smoother appearance. In 2018, there were >2,600,000 dermal filling procedures performed in the US, and the market was estimated to reach $10 billion by 2023. Despite the high demand, no dermal filler has been approved by FDA for injection in the superior portion of the face. High blood vessel density around the eye presents the risk for vascular occlusion leading to skin necrosis or blindness. UCLA researchers led by Prof. Timothy Deming and Michael Delong reported a novel dermal filler material, polyion-complex deblock copolypeptide hydrogels (PIC-DCH), which is safer than the currently used hyaluronic acid.
The field of brain-machine interfaces has advanced significantly over the past two decades, especially in its successful transition into human clinical trials. However, this progress has relied largely on wired, invasive sensors for the acquisition of neural data with high spatial and temporal resolution. Neurograins represents the first completely wireless network of sensors in neural application, consists of ensembles of implantable, sub-millimeter, individually addressable microchips.
Foodborne illness is a significant health and economic problem globally. Cross-contamination of food by pathogens via surfaces of food processing equipment is a leading risk factor in foodborne disease outbreaks. Antimicrobial coatings that make food contact surfaces self-sanitizing have potential to reduce cross-contamination and represent a $2.3B market opportunity. Despite that promise, the antimicrobial coating technology available for food contact surface applications is severely limited by a lack of food-grade coatings, lack of efficacy in high volume/organic matter environments, difficult application, high cost and challenges in use with legacy equipment. We have developed novel antimicrobial coatings to make food contact surfaces self-sanitizing to prevent cross-contamination. The coatings are made of food-grade, FDA GRAS materials. They are safe, effective, low-cost, environmentally friendly and useable on legacy equipment. The underlying technology was developed at University of California-Davis.
Monoclonal antibodies (mAbs) are a $300B market, about $20B in diagnostics and $30B in antiviral therapeutics. Yet antibodies require poorly scaling, expensive mammalian cells, vary with batch, are environmentally unstable, and are subject to escape by viral strain evolution. Protein Architects is developing beta solenoid proteins as “molecular Legos” for applications in self-assembly of nanoparticle based devices and materials. Our polyvalent, environmentally robust viral decoy proteins for antigen diagnostics and therapeutics can be scalably produced in microbial GMP facilities at 1/50 the cost per binder yet bind up to 1000000x stronger than antibodies. As receptor decoys, they align with viral evolution, and modular human design makes immunocompatible therapeutics. We are seeking seed financing and regulatory advising on our in development viral decoy antibody substitutes for SARS-CoV-2 antigen diagnostics and therapeutics. We are positioned to make a difference in this pandemic, and future viral threats.
The continuous emergence and rapid spread of antibiotic resistant bacteria and antimicrobial resistant Candida has caused serious environmental and public health issues worldwide due to increasing difficulty in treating infections. Triggered drug delivery systems that limit exposure to antibacterials and/or antimicrobials can alleviate these challenges and help prevent resistance. We have developed responsive hydrogel systems to combat skin wound bacterial and fungal infections. ResponseGels is developing hydrogels that incorporate a degradable peptide sequence in the backbone that responds specifically to either 𝛽‐lactamases (βLs), the most common cause of resistance to antibiotics, or aspartic proteases (Saps) secreted by virulent Candida.
Neuromodulation is a rapidly expanding field of clinical neuroscience. Yet the widespread use of neuronal probes for recording and functional stimulation has been slow to develop, in part because of incompatibility problems with existing metallic and ceramic probes, as well as surgical complexity and potential tissue damage or infection during probe insertion. SME-Tronic is developing an electrode array made of shape-memory alloys and/or shape-memory polymers that can be inserted in a minimally invasive fashion through a needle or a small window in the spine or skull. Once inserted, the temperature-driven shape-memory response transforms the electrode shape into a shape that covers a more desirable area of the brain or spinal cord.
Neuralert offers non-invasive, wearable wristband devices which monitor asymmetric arm movement/weakness, a tell-tale sign of stroke. Neuralert’s proprietary algorithm accurately identifies stroke symptoms and immediately alerts medical staff to assess the patient and begin treatment. Neuralert’s technology can detect stroke in under an hour, which is more than 4 times faster than manual assessment processes currently used. The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has most recently granted Neuralert designation as a Breakthrough Device. Neuralert is searching for an advisory board member as they complete their seed round of fundraising.
Current point of care diagnostics frequently require blood draws (e.g., blood glucose monitoring for diabetes), hampering our ability to continuously monitor biomarkers such as cortisol and electrolyte levels. Understanding these levels are critical for a range of populations (high-performance athletes, military personnel, the chronically ill). Today, these biomarker analytes can be isolated from sweat with a new platform from FESSwise. The FESSwise platform is capable of broad biomarker monitoring and is pursuing cortisol detection as a first indication. The Freestanding Electrochemical Sensing System (FESS) platform features sweat sampling, electrochemical sensing, and data display / transmission, all within a self-contained wearable platform. The FESS-enabled smartwatch can be used to monitor the metabolite profiles of individuals in sedentary and high-intensity exercise settings.
While deep learning methods exist to guide protein optimization, examples of novel proteins generated with these techniques require a priori mutational data. Aperiam is taking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry. We have trained a portfolio of computer vision algorithms on protein chemistry and use those algorithms to mutate genes for improved catalysis, expression, stability, and solubility. We are now using this approach to build our own suite of stabilized and solubilized enzyme therapeutics for direct delivery to the lung via nebulization and in parallel tailoring the computer vision framework to antibodies for expedited development and improved manufacturability.
SOLUtion Medical is an early-stage life science company developing user-friendly delivery systems for reconstitutable drugs. These devices improve patient outcomes through increased adherence to patient injected life-saving medication. We specifically aim to improve the administration efficacy of life-saving injectable medication with our TwistJect auto-injector for people living with adrenal insufficiency including Addison’s Disease and Congenital Adrenal Hyperplasia.
LignaMed is a biotechnology company developing breakthrough treatments for asthma, organ transplant viability, and pulmonary fibrosis. Many of these conditions suffer from localized ischemia-reperfusion injury due to local hypoxia. LignaMed's lead candidate LGM2605 is a novel small molecule synthetic lignan with anti-inflammatory and antioxidant properties. LignaMed expects to file an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) in 2021 for Airway Hyperreactivity (AHR) in Th2-low asthma, a subtype of glucocorticoid resistant asthma. LignaMed is recruiting a CEO to take its breakthrough pharmaceutical and device technologies from pre-clinical studies to clinical trials and FDA approval and/or exit with a strategic pharmaceutical or device company.
KIN-Therapeutics is developing an AI-based computational platform integrating structural bioinformatics and machine learning with experimental approaches to identify small molecules targeting specific protein kinase targets and conformations. The Kinase Inhibitor (KIN) artificial intelligence (AI) is able to generate de novo kinase drugs with optimal selectivity. This technology will allow for better design and discovery of clinically relevant kinase inhibitors, which will have significant implications for cancer, Alzheimer’s disease, and even diabetes treatments. KIN focuses on a manageable and clinically-relevant chemical space and is entering into a partnership with a biotech company to design conformation specific immune-oncology inhibitors. KIN is looking for a CEO / Chair of the Board to lead the next steps for the venture.
There are over 900k cocaine addicts in the USA alone while worldwide cocaine usage rates have been growing at over 2% a year over the last decade. In the USA this results in over 15k deaths, 505k ER visits and $21B lost annually. Despite all of this, there is currently no FDA approved treatment for cocaine abuse disorder. AddGraft Therapeutics aims to be the first FDA approved treatment for cocaine abuse disorder utilizing our revolutionary gene delivery platform. Our treatment promises to be long lasting, minimally invasive and highly effective at treating the challenging aspects of addiction. AddGraft's technology is a novel skin-based gene delivery platform for treating cocaine abuse. Patients receive an autologous skin graft of genetically modified skin-stem cells which produces a dual molecule solution to effectively break down cocaine, preventing lethal overdose, and to behaviorally prevent frequent use, relapse, and developing of new addictive behaviors.
Between 2007 and 2017, there has been a 377% increase in the treatment of diagnosed anaphylactic reactions to food. The current standard of care is not enough to stem the tide of patients suffering the healthcare costs of food allergies. Phlaxis is an innovative immune tolerance company focused on providing a new approach to treating food allergies. Phalxis' allergen tolerance platform features proteins, or antigens, that are engineered to deliver precise, targeted allergy therapy, without the side effects of broad immunosuppression. Phalxis’ allergen-specific platform can be translated to virtually any food allergy, including the Big 8 of milk, eggs, peanuts, tree nuts, fish, crustacean shellfish, wheat, and soy.
Detecting and quantifying very low concentrations of disease biomarkers is important for the diagnosis and management of many disease conditions in their early phases. Technologies to detect low concentrations of biomarkers are only available in the advanced research or central clinical laboratories, due to high technology complexity and costs causing significant delay in reaching correct diagnosis. Instanosis testing platform enables ultrasensitive, low-cost and rapid quantitation of disease biomarkers. This platform has many applications in multiple instances, where rapid, convenient and ultra-sensitive biomarker detection is crucial for disease detection and treatment. The lead application is the ultrasensitive detection of SARS-CoV-2 antigen in the community setting using smartphones. Current diagnostic gold standard for SARSCoV- 2 is rRT-PCR, which requires expensive extraction instrument, thermocycler, facilities and trained operators to conduct and hours or days to turn around results.
Smell loss is an early indicator of infectious and neurodegenerative disorders. In COVID-19, for example, objective smell loss may occur in >90% of patients. Though molecular (PCR) tests are effective in diagnosing SARS-CoV-2 infection, with moderate sensitivity and high specificity, they typically are costly (>$50), with long turnaround times (up to 5-7 days) and have not been as effective in controlling asymptomatic spread. The Aromha Smell Test complements molecular tests with high sensitivity and negative predictive value and can be scaled quickly to provide an important new tool to prevent community spread of COVID, with an at-home, non-invasive, safe, and cost-effective screening test that provides instantaneous results. This platform technology, developed based on 20 years of olfactory research at Harvard, can also be utilized to provide an early signal and improve care in critical neurodegenerative diseases such as Alzheimer's, Parkinson's Disease, and Traumatic Brain Injury.
IMIJ Technologies is a startup from the labs of Columbia’s Dr. Scott Small and Dr. Frank Provenzano that focuses on novel approaches to broad neurological and psychiatric screening and diagnostics that can be applied to existing and conventional neuroimaging - structural MRI. IMIJ has successfully developed and adapted technologies initially researched at Columbia to a variety of existing conventional neuroimaging to develop statistically rigorous candidate biomarkers, as well a fully interpretable report detailing the results. IMIJ uses the same images frequently obtained to diagnose brain diseases, images acquired tens of millions of times a year in the US alone. IMIJ's proprietary software requires no additional data or MRI equipment. IMIJ has raised $1.1M seed funding to date and is seeking $9M with the goal of securing approval for indication in order to refine the development and pilot with a major hospital system.